Verve Therapeutics

Calling all #biotech engineers! We're looking for an Engineer, Process Development, to join Verve. In this role, you will play an integral role in a team responsible for development of RNA manufacturing processes for our novel #geneediting therapies. The ideal candidate will have experience with nucleic acid process development technology, including both synthesis and downstream processing of oligonucleotide drug substances. This is a highly collaborative and cross-functional role. If this sounds like you, take a look at the opportunity here: https://lnkd.in/dXDY3ebU 

Another year, another successful American Heart Association #HeartWalk in Boston! ❤️ With 137 walkers across 10 teams, we’re proud to have reached our fundraising goal, contributing toward Boston’s overall goal of $1.2 million to improve health and help significantly reduce #heart disease and stroke death rates. Learn more about this important initiative here: https://lnkd.in/dVT7rhta

We’re excited to welcome the newest members of our team! As we continue to push the boundaries of #geneediting for #cardiovascular diseases, having talented and passionate individuals on board is key to achieving our mission. Learn more about our culture, the connections we make and open roles at Verve here: https://lnkd.in/euwGT56

Our co-founder and CEO Sekar (Sek) Kathiresan will participate in a plenary session at the American Society of Nephrology #KidneyWk in San Diego and speak to the development of #geneediting medicines for #cardiovascular health. If you’re attending, catch the presentation at 9 a.m. on October 25, and learn more about the session here: https://lnkd.in/dgYwwEQ7

Our Vice President of Genomic Medicine, Amit Khera, will be presenting at this year’s #ESGCT Annual Congress in Rome. He will discuss Verve’s mission of developing single-course #geneediting medicines to help treat patients living with #cardiovascular disease. Read more about the event here: https://lnkd.in/efye-f8c

It’s time for the second installment of #VerveVocab, a bimonthly series featuring Verve team members taking complex scientific vocabulary and making them crystal clear. This time, we’re diving into “proprotein convertase subtilisin/kexin type 9”, better known as PCSK9. The PCSK9 gene plays a critical role in controlling blood LDL-C (or low-density lipoprotein cholesterol) levels through regulation of the LDL receptor. Reducing PCSK9 proteins in the blood improves the ability of the liver to clear LDL-C, lowering the risk of developing #heartdisease. Learn more from Joe Biedenkapp, PhD, Chelsey Jensen and Yasser M. El-Gamal in the video below.

In honor of #HispanicHeritageMonth, we were delighted to welcome Harlisa Minaya-Ebai, SHRM-CP’s mother to our office to share the flavors of home-cooked Dominican cuisine. Moments like these remind us of the beauty and diversity of Latinx culture, and we’re proud to celebrate the contributions of our Hispanic and Latinx colleagues.

In our next segment of Understanding Delivery Systems, we're introducing you to the novel liver delivery system created by our team: the GalNAc-LNP. The GalNAc-LNP was initially developed for our VERVE-201 program to address an important challenge with delivery to the liver in people with homozygous familial hypercholesterolemia (HoFH), since patients with HoFH do not have LDL receptors on the surface of their liver cells, making standard lipid nanoparticle, or #LNP, delivery ineffective. We believe the GalNAc-LNP provides a best-in-class liver delivery system. Learn more in the video below, and reference our website here for additional information: https://lnkd.in/dPSdQrnW

Each quarter, our team hosts a poster session to share the cutting-edge research happening here at Verve. These sessions showcase our commitment to continuous learning and growth, and give us a chance to empower Vervians to stay at the forefront of #cardiovascular research.

We recently held an employee-led fireside chat about exploring career development opportunities within the workplace. Special thanks to Vervians Ananda Mishra and Zunera Khan for hosting the event and to our panelists for your insights about navigating new professional paths.